Advanced search
Publication Cover
Cancer Investigation Volume 39, 2021 - Issue 6-7
Submit an article Journal homepage
1,000
Views
8
CrossRef citations to date
0
Altmetric
Research Article

Efficacy and Safety of Trastuzumab Emtansine in Her2 Positive Metastatic Breast Cancer: Real-World Experience

Aykut Bahçecia Department of Medical Oncology, Dr. Ersin Arslan Education and Research Hospital, Gaziantep, TurkeyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7921-5204
ORCID Icon,
Semra Paydaşb Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, TurkeyORCID Iconhttps://orcid.org/0000-0003-4642-3693
ORCID Icon,
Naziye Akc Department of Medical Oncology, Institute of Oncology, İstanbul University, İstanbul, TurkeyORCID Iconhttps://orcid.org/0000-0001-5790-7066
ORCID Icon,
Ferhat Ferhatoğluc Department of Medical Oncology, Institute of Oncology, İstanbul University, İstanbul, TurkeyORCID Iconhttps://orcid.org/0000-0002-7651-6789
ORCID Icon,
Pınar Mualla Saipc Department of Medical Oncology, Institute of Oncology, İstanbul University, İstanbul, TurkeyORCID Iconhttps://orcid.org/0000-0001-6871-8519
ORCID Icon,
Gülşah Seydaoğlud Department of Biostatistics, University of Cukurova, Adana, TurkeyORCID Iconhttps://orcid.org/0000-0002-0899-894X
ORCID Icon,
Mehmet Bilicie Department of Medical Oncology, Faculty of Medicine, Atatürk University, Erzurum, Turkey
,
Melih Şimşeke Department of Medical Oncology, Faculty of Medicine, Atatürk University, Erzurum, Turkey
,
Salim Başol Tekine Department of Medical Oncology, Faculty of Medicine, Atatürk University, Erzurum, Turkey
,
Züleyha Çalikuşuf Department of Medical Oncology, Acibadem Adana Hospital, Acibadem MAA University, Adana, TurkeyORCID Iconhttps://orcid.org/0000-0003-0875-1485
ORCID Icon,
Sinan Yavuzf Department of Medical Oncology, Acibadem Adana Hospital, Acibadem MAA University, Adana, TurkeyORCID Iconhttps://orcid.org/0000-0002-1479-6439
ORCID Icon,
Ahmet Bilgehan Şahing Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, TurkeyORCID Iconhttps://orcid.org/0000-0002-7846-0870
ORCID Icon,
Erdem Çubukçug Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, TurkeyORCID Iconhttps://orcid.org/0000-0002-0070-0889
ORCID Icon,
Türkkan Evrenselg Department of Medical Oncology, Faculty of Medicine, Uludag University, Bursa, TurkeyORCID Iconhttps://orcid.org/0000-0002-9732-5340
ORCID Icon,
Serkan Değirmencioğluh Department of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli, TurkeyORCID Iconhttps://orcid.org/0000-0002-1213-2778
ORCID Icon,
Atike Gökçen Demirayh Department of Medical Oncology, Faculty of Medicine, Pamukkale University, Denizli, TurkeyORCID Iconhttps://orcid.org/0000-0003-4397-5468
ORCID Icon,
Perran Fulden Yumuki Division of Medical Oncology, School of Medicine, Marmara University, Istanbul, TurkeyORCID Iconhttps://orcid.org/0000-0001-8650-299X
ORCID Icon,
Özkan Alani Division of Medical Oncology, School of Medicine, Marmara University, Istanbul, TurkeyORCID Iconhttps://orcid.org/0000-0002-6635-2012
ORCID Icon,
Duygu İlke Çikmanj Department of Medical Oncology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
,
Fuat Hulusi Demirellij Department of Medical Oncology, Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey
,
Osman Köstekk Department of Medical Oncology, Trakya University, Edirne, TurkeyORCID Iconhttps://orcid.org/0000-0002-1901-5603
ORCID Icon,
Ali Gökyerk Department of Medical Oncology, Trakya University, Edirne, TurkeyORCID Iconhttps://orcid.org/0000-0002-1653-6155
ORCID Icon,
Mutlu Doğanl Department of Medical Oncology, Numune Education and Research Hospital, University of Health Sciences, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0001-9359-3770
ORCID Icon,
Öznur Ball Department of Medical Oncology, Numune Education and Research Hospital, University of Health Sciences, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0002-6901-2646
ORCID Icon,
Burcu Çakarm Department of Medical Oncology, Ege University, Izmir, TurkeyORCID Iconhttps://orcid.org/0000-0003-3790-791X
ORCID Icon,
Erhan Gökmenm Department of Medical Oncology, Ege University, Izmir, TurkeyORCID Iconhttps://orcid.org/0000-0003-4596-2986
ORCID Icon,
Deniz Yamaçn Department of Medical Oncology, Ankara Güven Hospital, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0002-9385-3875
ORCID Icon,
Taner Korkmazo Acıbadem MAA University School of Medicine, Medical Oncology Division, Acibadem Research Institiute of Senology (Maslak Hospital)ORCID Iconhttps://orcid.org/0000-0003-4292-0545
ORCID Icon,
Altay Aliyevp Department of Medical Oncology, Faculty of Medicine, Bezmialem University, Istanbul, TurkeyORCID Iconhttps://orcid.org/0000-0002-2024-7751
ORCID Icon,
Özge Keskinq Department of Medical Oncology, Selçuk University, Konya, TurkeyORCID Iconhttps://orcid.org/0000-0002-8062-0116
ORCID Icon,
Semiha Urvayr Department of Medical Oncology, Acibadem Kayseri Hospital, Acibadem MAA University, Kayseri, TurkeyORCID Iconhttps://orcid.org/0000-0002-0181-3842
ORCID Icon,
Mahmut Büyükşimşekb Department of Medical Oncology, Faculty of Medicine, Cukurova University, Adana, Turkey
,
Cemile Karadenizs Department of Medical Oncology, Hatay Antakya State Hospital, Hatay, Turkey
,
Birol Yildizt Department of Medical Oncology, Gulhane Education and Research Hospital, University of Health Sciences, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0001-8920-6467
ORCID Icon,
Havva Yeşil Çinkiru Department of Medical Oncology, Gaziantep University, Gaziantep, TurkeyORCID Iconhttps://orcid.org/0000-0002-7870-8741
ORCID Icon,
Hacer Demirv Department of Medical Oncology, Kayseri Education and Research Hospital
,
İsmail Beypinarw Department of Medical Oncology, Faculty of Medicine, Afyon Kocatepe University, Afyonkarahisar, TurkeyORCID Iconhttps://orcid.org/0000-0002-0853-4096
ORCID Icon,
Cengiz Karaçinx Department of Medical Oncology, Ankara Diskapi Education and Research Hospital, University of Health Sciences, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0002-7310-9328
ORCID Icon,
Kadir Esery Department of Medical Oncology, Mersin University, Mersin, TurkeyORCID Iconhttps://orcid.org/0000-0001-8666-6177
ORCID Icon,
Meltem Baykaraz Department of Medical Oncology, Faculty of Medicine, Sakarya University, Sakarya, TurkeyORCID Iconhttps://orcid.org/0000-0003-3291-8134
ORCID Icon,
Saadettin Kiliçkapaa Department of Medical Oncology, Faculty of Medicine, Hacettepe University, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0003-1637-7390
ORCID Icon,
Kerem Okuturbb Department of Medical Oncology, Istanbul Memorial Bahcelievler Hospital, Istanbul, TurkeyORCID Iconhttps://orcid.org/0000-0002-8079-7739
ORCID Icon,
Gülcan Bulutcc Department of Medical Oncology, Antakya Defne Hospital, Hatay, TurkeyORCID Iconhttps://orcid.org/0000-0001-7382-0972
ORCID Icon,
Ali Alkandd Department of Medical Oncology, Mugla Sıtkı Kocman University, Mugla, TurkeyORCID Iconhttps://orcid.org/0000-0002-8253-5046
ORCID Icon,
Erkan Arpaciee Department of Medical Oncology, Kocaeli Gebze Medicalpark Hospital, Kocaeli, Turkey
,
Kezban Nur Pilanciff Department of Medical Oncology, Istanbul Aydın University, Istanbul, Turkey
,
Atakan Demirn Department of Medical Oncology, Ankara Güven Hospital, Ankara, TurkeyORCID Iconhttps://orcid.org/0000-0002-1940-4086
ORCID Icon,
Deniz Işika Department of Medical Oncology, Dr. Ersin Arslan Education and Research Hospital, Gaziantep, Turkey
&
Nilgün Yildirima Department of Medical Oncology, Dr. Ersin Arslan Education and Research Hospital, Gaziantep, Turkey
 show all
Pages 473-481 | Received 12 Sep 2020, Accepted 16 May 2021, Published online: 07 Jun 2021

References

  • Tevaarwerk AJ, Gray RJ, Schneider BP, Smith ML, Wagner LI, Fetting JH, et al. Survival in patients with metastatic recurrent breast cancer after adjuvant chemotherapy: little evidence of improvement over the past 30 years. Cancer. 2013;119(6):1140–1148. doi:10.1002/cncr.27819.
  • Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31(31):3997–4013. doi:10.1200/JCO.2013.50.9984.
  • Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235(4785):177–182. doi:10.1126/science.3798106.
  • Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN, et al. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14(4):320–368. doi:10.1634/theoncologist.2008-0230.
  • Lewis Phillips GD, Li G, Dugger DL, Crocker LM, Parsons KL, Mai E, et al. Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res. 2008;68(22):9280–9290. doi:10.1158/0008-5472.CAN-08-1776.
  • Junttila TT, Li G, Parsons K, Phillips GL, Sliwkowski MX. Trastuzumab-DM1 (T-DM1) retains all the mechanisms of action of trastuzumab and efficiently inhibits growth of lapatinib insensitive breast cancer. Breast Cancer Res Treat. 2011;128(2):347–356. doi:10.1007/s10549-010-1090-x.
  • Verma S, Miles D, Gianni L, Krop IE, Welslau M, Baselga J, et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012;367(19):1783–1791. doi:10.1056/NEJMoa1209124.
  • Krop IE, Kim S-B, Martin AG, LoRusso PM, Ferrero J-M, Badovinac-Crnjevic T, et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. Lancet Oncol. 2017;18(6):743–754. doi:10.1016/S1470-2045(17)30313-3.
  • Perez EA, Barrios C, Eiermann W, Toi M, Im Y-H, Conte P, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab plus taxane for human epidermal growth factor receptor 2-positive, advanced breast cancer: primary results from the phase III MARIANNE study. JCO. 2017;35(2):141–148. doi:10.1200/JCO.2016.67.4887.
  • Early Breast Cancer T, Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365(9472):1687–1717.
  • Perez EA, Barrios C, Eiermann W, Toi M, Im Y‐H, Conte P, et al. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: final results from MARIANNE. Cancer. 2019;125(22):3974–3984. doi:10.1002/cncr.32392.
  • Fabi A, De Laurentiis M, Caruso M, Valle E, Moscetti L, Santini D, et al. Efficacy and safety of T-DM1 in the 'common-practice' of HER2+ advanced breast cancer setting: a multicenter study. Oncotarget. 2017;8(38):64481–64489. doi:10.18632/oncotarget.16373.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.